SOCS1 counteracts ROS-mediated survival signals and promotes apoptosis by modulating cell cycle to increase

Ji-Yoon Ryu1, Jiyoung Oh1, Su-Min Kim1

  • 1Laboratory of Immunology, Department of Biological Science, College of Natural Science, Sungkyunkwan University, Suwon 16419, Korea.

BMB Reports
|March 24, 2022
PubMed

Insights

Suppressors of cytokine signaling 1 (SOCS1) enhance colorectal cancer radiosensitivity by blocking survival signals and promoting apoptosis. SOCS1 induction may improve radiation therapy efficacy in tumors with low SOCS1 levels.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Suppressors of cytokine signaling (SOCS) proteins, including SOCS1, play complex roles in cancer, acting as both pro-tumor and anti-tumor factors.
  • Previous research indicated SOCS1 suppresses epithelial-to-mesenchymal transition in colorectal cancer (CRC) under radiation or oxidative stress.
  • This study investigates SOCS1's radiosensitizing potential as an anti-tumor mechanism in CRC.

Discussion:

  • SOCS1 overexpression in HCT116 cells shifted radiation-induced cell cycle arrest from G2/M to G1, promoting p53-dependent apoptosis.
  • SOCS1 knockdown reduced apoptosis and G1 arrest, highlighting SOCS1's crucial role in radiation response.
  • SOCS1 mediated its effect by inhibiting radiation-induced Jak3/STAT3 and Erk signaling, counteracting ROS-mediated survival signals.

Key Insights:

  • SOCS1 promotes radiosensitivity in colorectal cancer cells by inhibiting ROS-mediated survival pathways.
  • SOCS1 blocks cell cycle progression from G1 to S and enhances p53 activation, leading to increased apoptosis upon radiation.
  • The findings establish SOCS1 as a key regulator of colorectal cancer cell response to ionizing radiation.

Outlook:

  • Inducing SOCS1 expression could enhance the therapeutic efficacy of radiation in colorectal cancer.
  • Targeting SOCS1 may represent a novel strategy to overcome radioresistance in specific cancer types.
  • Further research could explore clinical applications of modulating SOCS1 levels in cancer radiotherapy.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K